Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Barings LLC Sells 238 Shares of JPMorgan Chase & Co. (NYSE:JPM)
Barings LLC lessened its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 11.5% during the 4th quarter, according...
M. Kulyk & Associates LLC Buys Shares of 952 JPMorgan Chase & Co. (NYSE:JPM)
M. Kulyk & Associates LLC bought a new stake in shares of JPMorgan Chase & Co. (NYSE:JPM – Free Report)...
Personal CFO Solutions LLC Trims Holdings in JPMorgan Chase & Co. (NYSE:JPM)
Personal CFO Solutions LLC lessened its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 2.3% during the fourth...
JPMorgan Chase & Co. (NYSE:JPM) is Atlantic Union Bankshares Corp’s 7th Largest Position
Atlantic Union Bankshares Corp lessened its stake in JPMorgan Chase & Co. (NYSE:JPM) by 0.4% in the fourth quarter, according...
Independent Advisor Alliance Purchases 478 Shares of M&T Bank Co. (NYSE:MTB)
Independent Advisor Alliance lifted its position in shares of M&T Bank Co. (NYSE:MTB – Free Report) by 29.9% in the...
Ellerson Group Inc. ADV Sells 506 Shares of JPMorgan Chase & Co. (NYSE:JPM)
Ellerson Group Inc. ADV decreased its holdings in JPMorgan Chase & Co. (NYSE:JPM) by 4.0% during the 4th quarter, according...